DeepMed Research

Laboratorios Sophia, S.A. de C.V.

🇲🇽Mexico

Country: 🇲🇽Mexico

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

Phase 3

Completed

Conditions: Primary Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: PRO-122
Drug: Krytantek Ofteno®

First Posted Date: 2017-08-22

Last Posted Date: 2019-12-09

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 60

Registration Number: NCT03257813

Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV)

Phase 4

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: PRO-087
Drug: Systane Ultra Preservative Free
Drug: Systane Ultra

First Posted Date: 2017-07-21

Last Posted Date: 2019-10-31

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 326

Registration Number: NCT03223909

Locations: 🇲🇽
Fernando Rodriguez Sixtos Higuera, Irapuato, Guanajuato, Mexico

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)

Phase 3

Terminated

Conditions: Primary Open-angle Glaucoma

Interventions: Drug: Timolol eye drops
Other: Placebo1
Drug: PRO-122
Drug: Dorzolamide-Timolol Ophthalmic
Other: Placebo 2
Drug: Brimonidine Ophthalmic Solution
Drug: Krytantek

First Posted Date: 2017-06-20

Last Posted Date: 2025-03-06

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 51

Registration Number: NCT03193333

Locations: 🇨🇴
MD. Sandra Belalcazar Rey, Bogotá, Bogotá D.C., Colombia
🇲🇽
MD. Victoria Eugenia Sanchez Castellanos, Zapopan, Jalisco, Mexico

Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)

Phase 2

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: PRO-157
Drug: Zymar®
Drug: Vigamox
Drug: Lagricel Ofteno®

First Posted Date: 2016-12-02

Last Posted Date: 2019-05-22

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 150

Registration Number: NCT02980523

Locations: 🇲🇽
Unidad Medica "Grupo Pediátrico", Guadalajara, Jalisco, Mexico

Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension

Phase 3

Terminated

Conditions: Ocular Hypertension
Primary Open Angle Glaucoma

Interventions: Drug: PRO-067
Drug: GAAP Ofteno®

First Posted Date: 2016-06-16

Last Posted Date: 2024-07-05

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 116

Registration Number: NCT02801617

Locations: 🇲🇽
Contract Research Organization, Zapopan, Jalisco, Mexico

Safety and Tolerability of the Ophthalmic Solution PRO-156 in Ophthalmologically Healthy Volunteers.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PRO-156

First Posted Date: 2013-06-06

Last Posted Date: 2019-10-25

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 30

Registration Number: NCT01871077

Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye

Phase 3

Completed

Conditions: Dry Eye

Interventions: Drug: PRO-148
Drug: Systane

First Posted Date: 2012-08-06

Last Posted Date: 2017-12-15

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 183

Registration Number: NCT01657253

Locations: 🇲🇽
Consultorio privado, Guadalajara, Jalisco, Mexico

Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification

Phase 2

Completed

Conditions: Phacoemulsification Cataract Surgery
Cataract

Interventions: Drug: Nevanac
Drug: PRO-155

First Posted Date: 2012-08-06

Last Posted Date: 2018-10-30

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 160

Registration Number: NCT01657266

Locations: 🇲🇽
Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico

Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis

Phase 3

Withdrawn

Conditions: Allergic Conjunctivitis

Interventions: Drug: Olopatadine Hydrochloride
Drug: PRO-118

First Posted Date: 2012-08-06

Last Posted Date: 2018-10-02

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Registration Number: NCT01657240

Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome

Phase 2

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: PRO-148 Ophthalmic Solution

First Posted Date: 2012-03-01

Last Posted Date: 2018-10-30

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 30

Registration Number: NCT01541891

Locations: 🇲🇽
Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Jalisco, Mexico

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy